Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
- 27 October 2006
- journal article
- Published by Elsevier in Schizophrenia Research
- Vol. 89 (1-3) , 91-100
- https://doi.org/10.1016/j.schres.2006.08.017
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Clozapine Alone versus Clozapine and Risperidone with Refractory SchizophreniaNew England Journal of Medicine, 2006
- Is There a Simple Way to Identify Insulin-Resistant Individuals at Increased Risk of Cardiovascular Disease?The American Journal of Cardiology, 2005
- Cost-Effective Screening for the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotic MedicationsAmerican Journal of Psychiatry, 2005
- Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs, 2005
- Prevalence of Hyperprolactinemia in SchizophreniaThe Journal of Clinical Psychiatry, 2004
- The Texas Medication Algorithm Project Antipsychotic Algorithm for SchizophreniaThe Journal of Clinical Psychiatry, 2004
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Focus on Antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?International Journal of Neuropsychopharmacology, 1999
- Mortality in schizophreniaThe British Journal of Psychiatry, 1998
- Comparative Study of Home Blood Glucose Monitoring Devices: Visidex, Chemstrip bG, Glucometer, and Accu-Chek bGDiabetes Care, 1983